BCRP
BCRP(breast cancer resistance protein), also called ABCG2 (ATP-binding cassette subfamily G member 2) is expressed in MDR (multi-drug resistance) diverse cancer cells. It protects cell from toxic xenobiotic substance in intestine, biliary tract, placenta, blood-testis barrier and blood-brain barriers.
Products for BCRP
- Cat.No. Product Name Information
- GC33099 BCRP-IN-1 BCRP-IN-1 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter.
- GC17215 Elacridar An inhibitor of MRP-1 and BCRP
- GC36034 FD 12-9 FD 12-9 is a flavonoid dimer, acts as a dual inhibitor of P-gp and BCRP, with EC50s of 285 nM and 0.9 nM, respectively. Anti-glioblastoma activity.
- GC10874 Fumitremorgin C multidrug transporter inhibitor
- GC12711 Ko 143 Inhibitor of the multidrug transporter BCRP
- GC14688 KS 176 inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter
- GC38129 ML753286 ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species.
-
GC18163
YHO-13177
A potent and specific inhibitor of BCRP
- GC32114 YHO-13351 YHO-13351 is the prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.
- GC33056 YHO-13351 free base YHO-13351 free base is the prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.
- GC32593 Zamicastat (BIA 5-1058) Zamicastat (BIA 5-1058) (BIA 5-1058) is a dopamine β-hydroxylase (DBH) inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects.